Successful management of lipid-lowering programs.
Health improvement programs must today face the hurdle of demonstrating their value to the business professionals in managed care organizations. These individuals have vast fiscal responsibilities but often lack a medical background. It is imperative that program advocates not only identify these key decision makers, but present an argument for program adoption by using data these decision-makers are most familiar with: grounded, quantitative results. This tactic can enhance the likelihood of a program being implemented. To validate the proposed program to the MCO business sector, it must address a disease or condition that is characterized by wide variation in physician practice, high cost, high volume, and an evidence base that supports the proposed intervention.
Wright
A T
AT
D000924:Anticholesteremic Agents / Q000191:economics / Q000627:therapeutic use*; D008078:Cholesterol, LDL / Q000097:blood; D003362:Cost-Benefit Analysis; D003657:Decision Making; D019468:Disease Management; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy* / Q000191:economics; D008329:Managed Care Programs / Q000592:standards*; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D014481:United States
D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL